Brought to you by 
BioFocus and UK company Xention to develop cardiac drugs
04 Nov 2002
Executive Summary
In a two-year agreement, BioFocus (bioinformatics) and newly formed UK company Xention Discovery (ion channel drug discovery) are looking to discover and develop candidates that interact with an ion channel target to treat atrial fibrillation, the most common type of cardiac arrhythmia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioFocus and UK company Xention to develop cardiac drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice